Noxopharm Share Price and Company Fundamentals
Last traded: Today at 4:59 AM
Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.
|Primary activities||Pharmaceuticals & biotechnology|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||828 Pacific Highway Suite 3 Level 4 Gordon NSW 2072 Australia|
|Phone / Fax||61 2 9144 2223 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Noxopharm does not pay dividends.
As of May 2021, following are the company executives and directors listed on Noxopharm.
|Dr. Graham Edmund Kelly||Founder, CEO, MD & Director||75||371.85k|
|Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.||Company Sec.||50|
|Mr. Shawn Van Boheemen||Chief Financial Officer|
|Ms. Jeanette Bell||Chief Operating Officer|
|Dr. John Wilkinson||Chief Scientific Officer|
|Dr. Gisela Mautner||Chief Medical Officer|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Noxopharm is 145.02M and its enterprise value is 126.43M. The enterprise value to revenue ratio of NOX is 21.34.
The NOX's stocks Beta value is 0.75 making it 25% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Noxopharm (NOX)
Noxopharm (ASX:NOX) Frequently Asked Questions
1. What is Noxopharm's Stock Symbol?
Noxopharm trades on ASX under the ticker symbol "NOX".
2. What is Noxopharm's stock price today?
One share of NOX stock can currently be purchased for approximately $0.525.
3. How can I contact Noxopharm?
Noxopharm's mailing address is 828 Pacific Highway Suite 3 Level 4 Gordon NSW 2072 Australia. The company can be reached via phone at 61 2 9144 2223.
4. What is Noxopharm's official website?
The official website of Noxopharm is http://www.noxopharm.com.
5. Which share registry manages Noxopharm's stock?
Noxopharm's stock is managed by AUTOMIC REGISTRY SERVICES.